Bernard Kelley Biography and Net Worth

Director of Codexis


Bernard J. Kelley serves as an Independent Chairman of the Board of the Board of the Company. Mr. Kelley brings to our board of directors experience in pharmaceutical manufacturing, as well as senior management and financial operations experience. From 1993 to 2002, Mr. Kelley was the President of the Merck Manufacturing Division, a division of Merck & Co., Inc. (“Merck”), a global pharmaceutical company, and he served as a member of the Merck Management Committee from 1995 to 2002. Mr. Kelley previously served on the board of directors of Aegis Analytical Corporation, an enterprise software company, from 2004 to 2006, and on the board of directors and compensation and audit committees of MAP Pharmaceuticals, Inc., a biotechnology company focused on developing inhalation-based therapies which was acquired by Allergan, Inc. in March 2013, from May 2007 to March 2013. In addition, Mr. Kelley serves as a member of the board of trustees and the finance committee of the Catholic Foundation of Greater Philadelphia, a non-profit organization based in Philadelphia, and as a member of the board of trustees and finance committee of the National Liberty Museum, also a non-profit organization based in Philadelphia. Mr. Kelley holds a B.S. in engineering from the U.S. Naval Academy.

What is Bernard J. Kelley's net worth?

The estimated net worth of Bernard J. Kelley is at least $950,286.96 as of April 21st, 2021. Mr. Kelley owns 206,136 shares of Codexis stock worth more than $950,287 as of November 23rd. This net worth evaluation does not reflect any other investments that Mr. Kelley may own. Learn More about Bernard J. Kelley's net worth.

How do I contact Bernard J. Kelley?

The corporate mailing address for Mr. Kelley and other Codexis executives is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. Codexis can also be reached via phone at (650) 421-8100 and via email at [email protected]. Learn More on Bernard J. Kelley's contact information.

Has Bernard J. Kelley been buying or selling shares of Codexis?

Bernard J. Kelley has not been actively trading shares of Codexis during the past quarter. Most recently, Bernard J. Kelley sold 2,500 shares of the business's stock in a transaction on Wednesday, April 21st. The shares were sold at an average price of $22.64, for a transaction totalling $56,600.00. Following the completion of the sale, the director now directly owns 206,136 shares of the company's stock, valued at $4,666,919.04. Learn More on Bernard J. Kelley's trading history.

Who are Codexis' active insiders?

Codexis' insider roster includes Byron Dorgan (Director), Bernard Kelley (Director), John Nicols (CEO), Dennis Wolf (Director), and Patrick Yang (Director). Learn More on Codexis' active insiders.

Are insiders buying or selling shares of Codexis?

In the last year, Codexis insiders bought shares 4 times. They purchased a total of 1,166,000 shares worth more than $3,514,910.00. The most recent insider tranaction occured on September, 25th when Major Shareholder Opaleye Management Inc. bought 5,000 shares worth more than $14,300.00. Insiders at Codexis own 2.1% of the company. Learn More about insider trades at Codexis.

Information on this page was last updated on 9/25/2024.

Bernard J. Kelley Insider Trading History at Codexis

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/21/2021Sell2,500$22.64$56,600.00206,136View SEC Filing Icon  
1/21/2021Sell2,500$24.98$62,450.00208,636View SEC Filing Icon  
10/21/2020Sell2,500$14.00$35,000.00211,136View SEC Filing Icon  
7/21/2020Sell2,500$12.79$31,975.00213,636View SEC Filing Icon  
4/21/2020Sell2,500$10.58$26,450.00207,184View SEC Filing Icon  
1/21/2020Sell2,500$18.00$45,000.00209,684View SEC Filing Icon  
9/6/2019Sell14,684$13.87$203,667.08226,868View SEC Filing Icon  
9/21/2018Sell10,207$18.12$184,950.84215,461View SEC Filing Icon  
8/30/2018Sell16,666$17.15$285,821.90242,334View SEC Filing Icon  
6/21/2018Sell10,206$16.58$169,215.48225,668View SEC Filing Icon  
3/21/2018Sell10,206$12.22$124,717.32View SEC Filing Icon  
8/24/2016Sell12,643$4.26$53,859.18234,906View SEC Filing Icon  
9/10/2015Sell5,200$3.45$17,940.00193,146View SEC Filing Icon  
See Full Table

Bernard J. Kelley Buying and Selling Activity at Codexis

This chart shows Bernard J Kelley's buying and selling at Codexis by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Codexis Company Overview

Codexis logo
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $4.61
Low: $4.30
High: $4.69

50 Day Range

MA: $3.42
Low: $2.85
High: $4.61

2 Week Range

Now: $4.61
Low: $1.85
High: $4.91

Volume

700,661 shs

Average Volume

543,340 shs

Market Capitalization

$375.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.07